China Dasheng Biotechnology Company (CDBT)

China Dasheng Biotechnology Company (CDBT) Financial Services Profile

China Dasheng Biotechnology Company, classified within the Financial Services sector as a Shell Company, primarily operates in the development and distribution of microbial products for agriculture and livestock in China. Its portfolio includes bacteria-based feed additives, crop enhancers, and biological preservatives, complemented by strategic investments in residential and commercial real estate.

What Is the Investment Thesis for CDBT?

China Dasheng Biotechnology Company (CDBT) presents a unique investment profile, operating within the biotechnology sector with a formal classification as a Shell Company in Financial Services, and trading on the OTC Other tier. The company's core value proposition stems from its specialized microbial products designed for agricultural and livestock enhancement in China. Key growth catalysts include the increasing global demand for sustainable agriculture and animal health solutions, which could drive adoption of its AM/HM bacteria-based additives and biological preservatives. The company's P/E ratio of 1.8 suggests it may be undervalued relative to its earnings, though this must be considered in the context of its $4.10M market capitalization and OTC listing. Its Beta of 2.26 indicates higher volatility compared to the broader market, reflecting potential for significant price swings. Additionally, CDBT's diversification into residential and commercial real estate offers an alternative asset base and potential for capital appreciation, mitigating some of the risks associated with a single industry focus. However, the "Shell Company" classification and OTC Other tier status necessitate thorough due diligence, as these factors often imply limited public disclosure and liquidity challenges. Investors would be evaluating the potential for its biotechnology segment to scale and gain market traction within China, alongside the performance of its real estate portfolio, against the backdrop of its current valuation metrics and operational transparency.

Based on FMP financials and quantitative analysis

CDBT Key Highlights

• Operates in the development and distribution of microbial products for agriculture and livestock, alongside real estate investments.
• Reports a P/E ratio of 1.8, indicating a potentially low valuation relative to earnings.
• Exhibits a Beta of 2.26, suggesting higher price volatility compared to the overall market.
• Maintains a workforce of 689 employees, supporting its biotechnology and real estate operations.
• Headquartered in Lanzhou, China, focusing its primary operations within the People's Republic of China.

Who Are CDBT's Competitors?

CDBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDBT's Key Strengths?

• Proprietary microbial product lines (AM/HM) for agriculture and livestock.
• Diversified business model with biotechnology and real estate investments.
• Established presence and operational base within the large Chinese market.
• Products address growing demand for sustainable and natural agricultural solutions.

What Are CDBT's Weaknesses?

• Small market capitalization ($0.00B) and low share price suggest significant financial risks.
• OTC Other tier listing implies limited transparency and potential liquidity challenges.
• Classification as a "Shell Company" in "Financial Services" may obscure core biotechnology operations.
• Reliance on the Chinese market introduces geopolitical and regulatory risks specific to the region.

What Could Drive CDBT Stock Higher?

• Potential for increased adoption of its AM/HM bacteria-based additives due to growing demand for sustainable agriculture in China.
• Successful development and market launch of new microbial products or enhanced formulations.
• Positive performance and appreciation of its residential and commercial real estate investments.
• Any future announcements regarding improved financial transparency or compliance with higher OTC tiers.
• Expansion of its distribution network or strategic partnerships within the Chinese agricultural sector.

What Are the Key Risks for CDBT?

• Financial-distress signal — its Altman Z-Score of -9.38 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Significant financial risks due to its $4.10M market capitalization and low share price, as well as its OTC Other tier listing.
• Lack of transparent financial disclosures makes it difficult for investors to assess true financial health and operational performance.
• High market volatility (Beta 2.26) and low liquidity inherent with OTC Other listed securities.
• Intense competition in both the agricultural biotechnology and real estate sectors in China.
• Regulatory changes or economic downturns in China could negatively impact both its biotechnology operations and real estate portfolio.

What Are the Growth Opportunities for CDBT?

• Expansion in Sustainable Agricultural Inputs: The global agricultural sector is increasingly shifting towards sustainable practices, driving demand for biological inputs like CDBT's AM/HM bacteria-based crop additives and foliar fertilizers. With growing awareness of soil health and reduced chemical use, there is a significant market opportunity for products that naturally enhance nutrient absorption and disease resistance. The Chinese market, a major agricultural producer, presents substantial potential for scaling these environmentally friendly solutions. This trend is expected to continue for the next 5-10 years, offering a sustained growth runway for companies providing effective, bio-based alternatives.
• Growing Demand for Animal Health and Nutrition Solutions: The livestock industry faces continuous pressure to improve animal health, growth rates, and feed efficiency, while also reducing antibiotic use. CDBT's AM/HM bacteria-based feed additives, which enhance feed texture, inhibit pathogens, and deliver essential nutrients, are well-positioned to meet these needs. The increasing focus on animal welfare and food safety standards globally and within China creates a robust market for advanced nutritional supplements. This market segment is projected to grow steadily over the next decade, driven by consumer demand for healthier animal products.
• Development of Novel Biological Preservatives: The market for biological preservatives, exemplified by CDBT's FGW bacterial preservatives, is expanding due to demand for extending the shelf life of agricultural produce and preserving biological specimens without harsh chemicals. As supply chains become more complex and scientific research intensifies, the need for effective, natural preservation methods grows. Innovations in this area can open new market segments and applications, providing CDBT with opportunities to license or expand its product offerings. This area could see significant growth over the next 3-7 years as industries seek safer and more sustainable preservation techniques.
• Leveraging Real Estate Portfolio for Capital Appreciation: Beyond its biotechnology operations, CDBT's investments in residential and commercial real estate offer a distinct growth avenue. Strategic management and development of these assets, particularly in a growing economy like China, can lead to significant capital appreciation and rental income. This diversification provides a hedge against potential volatility in the biotechnology sector and offers a stable, tangible asset base. The performance of this portfolio is tied to regional economic development and property market trends, with potential for long-term value creation over a 5-15 year horizon.
• Strategic Partnerships and Market Penetration in China: Given its operational base in Lanzhou, China, CDBT has the opportunity to forge strategic partnerships with local agricultural cooperatives, large-scale farms, and animal husbandry enterprises. Such collaborations can significantly enhance market penetration and distribution channels for its microbial products across various provinces. Expanding its sales network and establishing strong relationships within the vast Chinese market could unlock substantial revenue growth. This localized strategy, focusing on regional needs and government initiatives for agricultural modernization, offers a clear path for expansion over the next 3-5 years.

What Opportunities Does CDBT Have?

• Increasing global and Chinese demand for sustainable agriculture and animal health products.
• Expansion of product applications for its microbial technologies into new segments.
• Potential for strategic partnerships to enhance distribution and market reach within China.
• Capital appreciation and rental income from its residential and commercial real estate portfolio.

What Threats Does CDBT Face?

• Intense competition from established biotechnology firms and agricultural input providers.
• Regulatory changes in China affecting agricultural practices, biotechnology, or real estate.
• Challenges in maintaining compliance with OTC listing requirements and disclosure standards.
• Economic downturns impacting consumer spending on agricultural products or the real estate market.

What Are CDBT's Competitive Advantages?

• Proprietary blends of Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) offer unique formulations.
• Specialized knowledge in microbial product development for specific agricultural and animal health applications.
• Established distribution network within the People's Republic of China for its biotechnology products.
• Diversified asset base through investments in real estate, providing a potential hedge and alternative revenue stream.

What Does CDBT Do?

China Dasheng Biotechnology Company, headquartered in Lanzhou, China, is a multifaceted enterprise primarily engaged in the creation, promotion, and distribution of microbial products across the People's Republic of China. Established with a focus on leveraging biotechnology for agricultural and animal husbandry improvements, the company's journey began as Max Nutrition, Inc., before rebranding to its current name in March 2008, signifying a strategic shift or expansion into its current operational scope. Its core product line is centered on specialized solutions that function as beneficial additives for both livestock feed and agricultural cultivation. For agricultural applications, CDBT's AM/HM bacteria-based additives for crops, featuring specific strains such as Bulgaria lactobacillus, beer microzyme, and dark red spirilla, are meticulously formulated. These additives are designed to significantly boost beneficial microbial populations within the soil, a critical factor for soil health and plant vitality. Concurrently, they work to counteract the proliferation of harmful fungi and putrefactive bacteria, thereby optimizing nutrient absorption by plants and helping to reduce the incidence of diseases in crops. The company also supplies bacteria-based fertilizers specifically intended for foliar application on vegetables and fruits, offering targeted nutrient delivery and protection. In the animal nutrition segment, CDBT's AM/HM bacteria-based feed additives are engineered to enhance the texture and palatability of livestock feed. Crucially, these additives inhibit the growth of pathogenic bacteria within the digestive systems of animals, contributing to overall animal health. Beyond pathogen control, they deliver a spectrum of essential nutrients, including organic acids, vitamins, enzymes, natural antibiotics, mycelial protein, and various other growth-promoting substances, ensuring a balanced nutritional profile in animal feed. Furthermore, the company's FGW bacterial preservatives serve a dual purpose: facilitating the preservation of animal specimens for scientific research and extending the shelf life of agricultural produce, addressing critical needs in both scientific and commercial sectors. Beyond its primary biotechnology endeavors, China Dasheng Biotechnology Company diversifies its asset base through investments in the residential and commercial real estate sectors, providing an additional revenue stream and asset diversification.

What Products and Services Does CDBT Offer?

• Develops and distributes proprietary Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM) products.
• Produces bacteria-based additives for crops to boost beneficial soil microbes and counteract harmful fungi.
• Manufactures bacteria-based feed additives for livestock to improve feed texture, inhibit pathogens, and deliver nutrients.
• Supplies FGW bacterial preservatives for animal specimen preservation and extending agricultural produce shelf life.
• Offers bacteria-based fertilizers for direct application onto plant foliage, particularly for vegetables and fruits.
• Holds investments in residential and commercial real estate sectors.
• Operates primarily within the People's Republic of China.

How Does CDBT Make Money?

• Generates revenue from the sale of microbial products, including crop additives, feed additives, and biological preservatives, to agricultural and livestock sectors.
• Derives income from its real estate investments, potentially through rental income or property sales.
• Focuses on proprietary blends of AM/HM technology, suggesting a value-added product strategy.
• Aims to improve agricultural yields and animal health, positioning its products as essential inputs for modern farming.

What Industry Does CDBT Operate In?

China Dasheng Biotechnology Company operates within a complex industry landscape, formally classified as a "Shell Company" in the "Financial Services" sector, yet actively engaged in biotechnology and real estate. The "Shell Company" designation often implies a vehicle for other operations or asset holding, which can introduce unique considerations for investors regarding transparency and active business. However, CDBT's operational focus on microbial products places it within the broader agricultural biotechnology market. This market is characterized by increasing demand for sustainable farming practices, improved crop yields, and enhanced animal health, driven by global population growth and environmental concerns. The competitive landscape for agricultural biotechnology includes established players and emerging innovators developing bio-pesticides, bio-fertilizers, and feed additives. CDBT's specific niche with AM/HM bacteria-based products positions it to capitalize on these trends within the Chinese market. Its real estate investments provide diversification, placing it also in the context of China's dynamic property market, which is influenced by economic growth, urbanization, and government policies.

Who Are CDBT's Key Customers?

• Agricultural enterprises and individual farmers seeking to enhance crop health and yields.
• Livestock farms and animal husbandry operations aiming to improve animal nutrition and health.
• Scientific research institutions requiring biological preservatives for specimen preservation.
• Food processing and distribution companies looking to extend the shelf life of agricultural produce.
• Tenants and buyers within its residential and commercial real estate portfolio.

How China Dasheng Biotechnology Company Is Valued

China Dasheng Biotechnology Company carries a market capitalization of $4.10M, placing it in the micro-cap category. Relative to its peer group, CDBT's quantitative score of 38/100 is below the peer average of 65/100.

Company Profile

China Dasheng Biotechnology Company operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Lanzhou, CN. The company is led by CEO Gang Chen. CDBT has traded publicly since 2008.

P/E 1.8Key Financial Metrics

CDBT trades at a trailing price-to-earnings ratio of 1.77, below the Financial Services sector average of ~18x. Its free cash flow yield is -7.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 62.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

China Dasheng Biotechnology Company's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.38 places it in the distress zone, a signal of elevated financial risk.

CDBT Financials

CDBT Latest News

No recent news available for CDBT.

CDBT Analyst Consensus

CDBT MoonshotScore

China Dasheng Biotechnology Company Financial Services Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources